Paul Tudor Jones's XERS Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 22,186 shares of Xeris Biopharma Holdings, Inc. (XERS) worth $175,713, representing 0.00% of the portfolio. First purchased in 2021-Q4, this medium-term investment has been held for 19 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in XERS, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2026, adding 85,228 shares. Largest reduction occurred in Q3 2023, reducing 216,913 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Xeris Biopharma Holdings (XERS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Xeris Biopharma Holdings (XERS) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | -85,228 | Reduce 79.35% | 22,186 | $7.92 |
| Q1 2026 | +85,228 | Add 384.15% | 107,414 | $5.80 |
| Q4 2025 | -15,808 | Reduce 41.61% | 22,186 | $7.85 |
| Q3 2025 | -187,192 | Reduce 83.13% | 37,994 | $8.14 |
| Q1 2025 | -80,000 | Reduce 26.21% | 225,186 | $5.49 |
| Q4 2024 | -202,171 | Reduce 39.85% | 305,186 | $3.39 |
| Q3 2024 | -65,829 | Reduce 11.48% | 507,357 | $2.85 |
| Q1 2024 | +19,775 | Add 3.57% | 573,186 | $2.21 |
| Q4 2023 | -88,087 | Reduce 13.73% | 553,411 | $2.35 |
| Q3 2023 | -216,913 | Reduce 25.27% | 641,498 | $1.86 |
| Q2 2023 | -101,700 | Reduce 10.59% | 858,411 | $2.62 |
| Q2 2022 | -1,081 | Reduce 0.11% | 960,111 | $1.54 |
| Q1 2022 | +1,081 | Add 0.11% | 961,192 | $2.56 |
| Q4 2021 | +960,111 | New Buy | 960,111 | $2.93 |
Paul Tudor Jones's Xeris Biopharma Holdings Investment FAQs
Paul Tudor Jones first purchased Xeris Biopharma Holdings, Inc. (XERS) in Q4 2021, acquiring 960,111 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Xeris Biopharma Holdings, Inc. (XERS) for 19 quarters since Q4 2021.
Paul Tudor Jones's largest addition to Xeris Biopharma Holdings, Inc. (XERS) was in Q4 2021, adding 960,111 shares worth $2.81 M.
According to the latest 13F filing for Q2 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 22,186 shares of Xeris Biopharma Holdings, Inc. (XERS), valued at approximately $175,713.
As of the Q2 2026 filing, Xeris Biopharma Holdings, Inc. (XERS) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Xeris Biopharma Holdings, Inc. (XERS) was 961,192 shares, as reported at the end of Q1 2022.